NO20065957L - Metastinderivater og anvendelse derav - Google Patents

Metastinderivater og anvendelse derav

Info

Publication number: NO20065957L
Authority: NO; Norway
Prior art keywords: metastine; derivatives; secretion; cancer; activity
Prior art date: 2004-06-25

Application number

NO20065957A

Other languages

English (en)

Norwegian (no)

Inventor

Chieko Kitada

Taiji Asami

Naoki Nishizawa

Original Assignee

Takeda Pharmaceutical

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-06-25

Filing date

2006-12-21

Publication date

2007-01-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34971534&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20065957(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-12-21 Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical

2007-01-25 Publication of NO20065957L publication Critical patent/NO20065957L/no

Links

230000001394 metastastic effect Effects 0.000 title abstract 2
206010061289 metastatic neoplasm Diseases 0.000 title abstract 2
230000000694 effects Effects 0.000 abstract 6
230000028327 secretion Effects 0.000 abstract 4
206010028980 Neoplasm Diseases 0.000 abstract 3
201000011510 cancer Diseases 0.000 abstract 3
206010027476 Metastases Diseases 0.000 abstract 2
229940088597 hormone Drugs 0.000 abstract 2
239000005556 hormone Substances 0.000 abstract 2
230000009401 metastasis Effects 0.000 abstract 2
150000001413 amino acids Chemical class 0.000 abstract 1
230000004071 biological effect Effects 0.000 abstract 1
239000008280 blood Substances 0.000 abstract 1
210000004369 blood Anatomy 0.000 abstract 1
230000005907 cancer growth Effects 0.000 abstract 1
239000000470 constituent Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Hematology (AREA)
Reproductive Health (AREA)
Immunology (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Gynecology & Obstetrics (AREA)
Neurosurgery (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Emergency Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Toxicology (AREA)
Molecular Biology (AREA)
Pregnancy & Childbirth (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)

NO20065957A 2004-06-25 2006-12-21 Metastinderivater og anvendelse derav NO20065957L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2004187671		2004-06-25
JP2004363311		2004-12-15
PCT/JP2005/012021 WO2006001499A2 (fr)	2004-06-25	2005-06-23	Derives de metastine et leur utilisation

Publications (1)

Publication Number	Publication Date
NO20065957L true NO20065957L (no)	2007-01-25

Family

ID=34971534

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20065957A NO20065957L (no)	2004-06-25	2006-12-21	Metastinderivater og anvendelse derav

Country Status (20)

Country	Link
US (2)	US7625869B2 (fr)
EP (2)	EP2113513B1 (fr)
JP (3)	JP4346650B2 (fr)
CN (2)	CN101845091A (fr)
AR (1)	AR049938A1 (fr)
AU (1)	AU2005257484A1 (fr)
BR (1)	BRPI0512397A (fr)
CA (1)	CA2571420A1 (fr)
CL (1)	CL2008003730A1 (fr)
CR (1)	CR8828A (fr)
IL (1)	IL179640A0 (fr)
MA (1)	MA28903B1 (fr)
MX (1)	MXPA06014206A (fr)
NO (1)	NO20065957L (fr)
NZ (1)	NZ552029A (fr)
PE (2)	PE20060371A1 (fr)
RU (1)	RU2006145886A (fr)
SG (1)	SG153865A1 (fr)
TW (1)	TW200607816A (fr)
WO (1)	WO2006001499A2 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003080149A2 (fr)	2002-03-20	2003-10-02	Mannkind Corporation	Appareil d'inhalation
CN1761680A (zh)	2002-12-26	2006-04-19	武田药品工业株式会社	肿瘤迁移抑制素衍生物及其用途
CA2518541C (fr)	2003-03-12	2013-05-21	Takeda Pharmaceutical Company Limited	Agents ameliorant la fonction gonadique
WO2005113147A2 (fr)	2004-04-08	2005-12-01	Biomatrica, Inc.	Integration du stockage et de la gestion d'echantillons pour les sciences de la vie
CA2571420A1 (fr)	2004-06-25	2006-01-05	Takeda Pharmaceutical Company Limited	Derives de metastine et leur utilisation
PL1786784T3 (pl)	2004-08-20	2011-04-29	Mannkind Corp	Kataliza syntezy diketopiperazyn
KR101644250B1 (ko)	2004-08-23	2016-07-29	맨카인드 코포레이션	약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
CN104324362B (zh)	2005-09-14	2018-04-24	曼金德公司	以提高活性试剂对结晶微粒表面的亲和力为基础的药物配制方法
US20090093615A1 (en) *	2005-12-22	2009-04-09	Takeda Pharmaceutical Company Limited	Metastin derivatives and use thereof
AR058584A1 (es)	2005-12-22	2008-02-13	Takeda Pharmaceutical	Derivados de metastina y uso de los mismos
US8404643B2 (en) *	2005-12-22	2013-03-26	Takeda Pharmaceutical Company Limited	Metastin derivatives and use thereof
IN2015DN00888A (fr)	2006-02-22	2015-07-10	Mannkind Corp
WO2007125619A1 (fr) *	2006-04-26	2007-11-08	Kyoto University	Nouveau compose ayant une activite agoniste de gpr54
ITMI20061607A1 (it)	2006-08-09	2008-02-10	Maria Vincenza Carriero	Peptidi con attivita farmacologica
JO3048B1 (ar) *	2006-10-25	2016-09-05	Takeda Pharmaceuticals Co	مشتقات متاستين واستخدامها
ZA200902452B (en) *	2006-10-25	2010-07-28	Takeda Pharmaceutical	Metastin derivatives and use thereof
EP2277900A4 (fr)	2008-04-24	2011-08-03	Takeda Pharmaceutical	Dérivé de métastine et son utilisation
EP2275433B1 (fr) *	2008-04-30	2017-06-07	Kyoto University	Dérivé de metastine et son utilisation
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
ES2929343T3 (es)	2008-06-13	2022-11-28	Mannkind Corp	Inhalador de polvo seco accionado por aspiración para la administración de fármacos
KR101628410B1 (ko)	2008-06-20	2016-06-08	맨카인드 코포레이션	흡입 활동에 관한 실시간 프로파일링을 위한 대화형 장치 및 방법
LT2314609T (lt) *	2008-07-30	2017-04-10	Takeda Pharmaceutical Company Limited	Metastino darinys ir jo panaudojimas
JP2012513982A (ja)	2008-12-29	2012-06-21	武田薬品工業株式会社	癌の予防・治療剤
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
WO2010137022A1 (fr)	2009-05-27	2010-12-02	Yeda Research And Development Co. Ltd	Agonistes ou antagonistes de gpr54 utiles dans le traitement de maladies impliquant des anomalies du comportement
CN102665690A (zh)	2009-12-22	2012-09-12	武田药品工业株式会社	缓释制剂
IL223742A (en)	2010-06-21	2016-06-30	Mannkind Corp	A dry powder inhaler and preparation for it
WO2012018639A2 (fr)	2010-07-26	2012-02-09	Biomatrica, Inc.	Compositions de stabilisation d'adn, d'arn, de protéines salivaires et d'autres échantillons biologiques lors du transport et du stockage à températures ambiantes
EP2598660B1 (fr)	2010-07-26	2017-03-15	Biomatrica, INC.	Compositions de stabilisation d'adn, d'arn, de protéines dans le sang et d'autres échantillons biologiques lors du transport et du stockage à températures ambiantes
AU2012236150B2 (en)	2011-04-01	2016-03-31	Mannkind Corporation	Blister package for pharmaceutical cartridges
WO2012174472A1 (fr)	2011-06-17	2012-12-20	Mannkind Corporation	Microparticules de dicétopipérazine de capacité élevée
EP2755690B1 (fr)	2011-08-04	2020-04-01	Merck Sharp & Dohme B.V.	Conjugués du kisspeptide avec un pentasaccharide
BR112014009686A2 (pt)	2011-10-24	2018-08-07	Mannkind Corp	composição analgésica inalável, pó seco e método para tratar dor
CN104350064A (zh)	2012-03-14	2015-02-11	耶达研究及发展有限公司	修饰的吻素肽和其用途
CN104619369B (zh)	2012-07-12	2018-01-30	曼金德公司	干粉药物输送系统和方法
US9725703B2 (en)	2012-12-20	2017-08-08	Biomatrica, Inc.	Formulations and methods for stabilizing PCR reagents
WO2014119753A1 (fr) *	2013-01-31	2014-08-07	学校法人東京薬科大学	Peptide inhibiteur de la myostatine
MX375448B (es)	2013-07-18	2025-03-06	Mannkind Corp	Composiciones farmacéuticas en polvo seco estables al calor y métodos.
US10220069B2 (en) *	2014-01-22	2019-03-05	The Johns Hopkins University	Compositions and methods for treating diabetes
US10307464B2 (en)	2014-03-28	2019-06-04	Mannkind Corporation	Use of ultrarapid acting insulin
ES2786373T3 (es)	2014-06-10	2020-10-09	Biomatrica Inc	Estabilización de trombocitos a temperaturas ambiente
KR20250047404A (ko)	2015-12-08	2025-04-03	바이오매트리카 인코포레이티드	적혈구 침강 속도의 감소
TWI778979B (zh)	2016-09-30	2022-10-01	瑞士商麥歐文科學有限公司	治療女性不孕症之方法
CN109206481B (zh)	2017-07-05	2023-08-18	尚华医药科技(江西)有限公司	一种肽类化合物、其应用及含其的组合物
CN108752233B (zh) *	2018-07-18	2020-10-16	河北师范大学	小分子凝胶因子、凝胶材料及制备方法和应用
US20230159450A1 (en) *	2020-05-08	2023-05-25	The Feinstein Institutes For Medical Research	Dimers for use in synthesis of peptidomimetics
WO2025217074A1 (fr)	2024-04-08	2025-10-16	Radionetics Oncology, Inc.	Agents thérapeutiques ciblant le récepteur de la kisspeptine (kiss1r) et leurs utilisations

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1524747A (en) *	1976-05-11	1978-09-13	Ici Ltd	Polypeptide
FR2488253A1 (fr) *	1980-08-08	1982-02-12	Roques Bernard	Nouveaux peptides et leur application en therapeutique
IL74827A (en) *	1984-05-21	1989-06-30	Salk Inst For Biological Studi	Peptides active as gnrh antagonists and pharmaceutical compositions containing them
MX9100717A (es) *	1990-08-24	1992-04-01	Syntex Inc	Antagonistas de la bradiquinina
US5824784A (en)	1994-10-12	1998-10-20	Amgen Inc.	N-terminally chemically modified protein compositions and methods
CN1200114A (zh)	1995-10-19	1998-11-25	武田药品工业株式会社	作为gnrh拮抗剂的喹啉衍生物
JPH09169735A (ja)	1995-10-19	1997-06-30	Takeda Chem Ind Ltd	キノリン誘導体、その製造法および用途
JP2000510453A (ja)	1996-04-19	2000-08-15	ノボノルディスクアクティーゼルスカブ	成長ホルモン遊離特性を有する化合物
WO1998039448A2 (fr)	1997-03-07	1998-09-11	Human Genome Sciences, Inc.	186 nouvelles proteines secretees
JP4486187B2 (ja)	1998-10-27	2010-06-23	武田薬品工業株式会社	新規ｇ蛋白質共役型レセプター蛋白質、そのｄｎａおよびそのリガンド
US6528054B1 (en)	1998-12-28	2003-03-04	Corixa Corporation	Compositions and methods for the therapy and diagnosis of breast cancer
PL353057A1 (en)	1999-06-28	2003-10-06	Basf Aktiengesellschaft	Method for preventing tumoral growth
US6638906B1 (en)	1999-12-13	2003-10-28	Nobex Corporation	Amphiphilic polymers and polypeptide conjugates comprising same
JP2001231581A (ja) *	1999-12-17	2001-08-28	Takeda Chem Ind Ltd	ＫｉＳＳ−１ペプチドの製造法
CN1411509A (zh) *	1999-12-17	2003-04-16	武田药品工业株式会社	Kiss－1肽的制造方法
JP2004526401A (ja)	2000-03-29	2004-09-02	コリクサコーポレイション	肺癌の治療および診断のための組成物および方法
AU2001244609A1 (en)	2000-03-30	2001-10-15	Takeda Chemical Industries Ltd.	Novel protein, dna thereof and process for producing the same
US7834141B1 (en)	2000-03-31	2010-11-16	Theresa Siler-Khodr	Non-mammalian GnRH analogs and uses thereof in tumor cell growth regulation and cancer therapy
RU2311920C2 (ru)	2000-09-20	2007-12-10	Корикса Корпорейшн	Композиции и способы для лечения и диагностики рака легких
JP2003026601A (ja)	2000-11-29	2003-01-29	Takeda Chem Ind Ltd	医薬組成物およびその製造法
JP2002320496A (ja)	2001-02-26	2002-11-05	Takeda Chem Ind Ltd	新規マウス型ＫｉＳＳ−１レセプタータンパク質およびそのＤＮＡ
WO2002085399A1 (fr)	2001-04-20	2002-10-31	Takeda Chemical Industries, Ltd.	Preparations contenant un peptide
KR100599419B1 (ko) *	2001-05-17	2006-07-10	가부시키가이샤 시마즈세이사쿠쇼	펩티드의 제조법
US7112662B2 (en) *	2001-09-19	2006-09-26	Takeda Pharmaceutical Company Limited	Anti-metasin antibodies and their methods of use
WO2003060125A1 (fr)	2002-01-11	2003-07-24	Takeda Chemical Industries, Ltd.	Procede de production du peptide kiss-1
JP2003300906A (ja)	2002-04-12	2003-10-21	Daiichi Fine Chemical Co Ltd	がん転移抑制因子の安定化
JPWO2004035089A1 (ja) *	2002-10-09	2006-02-09	協和醗酵工業株式会社	ホルモン依存性癌の治療剤
DE60327344D1 (de)	2002-10-25	2009-06-04	Takeda Pharmaceutical	Gpr54 'knock-out' säugetiere und screening-verfahren, die sie verwenden
CN1761680A (zh) *	2002-12-26	2006-04-19	武田药品工业株式会社	肿瘤迁移抑制素衍生物及其用途
JP4804714B2 (ja)	2002-12-26	2011-11-02	武田薬品工業株式会社	メタスチン誘導体およびその用途
US6800611B2 (en) *	2003-01-06	2004-10-05	Takeda Chemical Industries, Ltd.	Metastin derivatives and their use
KR100595364B1 (ko)	2003-02-20	2006-07-03	재단법인 목암생명공학연구소	Ｌｋ8 단백질을 유효성분으로 포함하는 항암제
CA2518541C (fr)	2003-03-12	2013-05-21	Takeda Pharmaceutical Company Limited	Agents ameliorant la fonction gonadique
EP1464652A1 (fr)	2003-04-02	2004-10-06	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Agoniste et antagoniste du récepteur GPR54 utiles pour le traitement des maladies associées à la gonadotrophine
US20050002935A1 (en)	2003-04-17	2005-01-06	Vincent Ling	Use of B7-H3 as an immunoregulatory agent
EP1618384A2 (fr)	2003-04-28	2006-01-25	Wyeth	Procedes et compositions permettant de moduler le recepteur 54 couple a une proteine g
WO2004101747A2 (fr)	2003-05-07	2004-11-25	The General Hospital Corporation	Identification et utilisation de gpr54 et de ses ligands pour les troubles de la reproduction et la contraception
EP1633702B1 (fr)	2003-05-30	2008-07-02	Prozymex A/S	Inhibiteurs de protease
EP1688498B1 (fr)	2003-11-03	2011-03-09	Beijing Sunbio Biotech Co., Ltd.	Proteine de recombinaison anticancereuse, ses genes codant et ses utilisations
RU2333221C2 (ru)	2003-11-03	2008-09-10	Бейцзин Санбио Байотек Ко., Лтд.	Рекомбинантный белок, обладающий противораковым действием, кодирующий его ген и его применение
WO2005095973A2 (fr)	2004-03-25	2005-10-13	Bayer Healthcare Ag	Methodes diagnostiques et therapeutiques pour des maladies associees au recepteur 54 couple a la proteine g (gpr54)
JP2007533748A (ja)	2004-04-23	2007-11-22	アプライドリサーチシステムズエーアールエスホールディングナームロゼフェンノートシャップ	不妊症の処置のためのｇｐｃｒ５４リガンドの使用
CA2571420A1 (fr)	2004-06-25	2006-01-05	Takeda Pharmaceutical Company Limited	Derives de metastine et leur utilisation
WO2007084211A2 (fr)	2005-11-11	2007-07-26	The General Hospital Corporation	Utilisation de ligands du gpr54 pour le traitement de troubles de la reproduction, de troubles proliferatifs et pour la contraception
US8404643B2 (en) *	2005-12-22	2013-03-26	Takeda Pharmaceutical Company Limited	Metastin derivatives and use thereof
AR058584A1 (es) *	2005-12-22	2008-02-13	Takeda Pharmaceutical	Derivados de metastina y uso de los mismos
US20090099334A1 (en) *	2005-12-22	2009-04-16	Takeda Pharmaceutical Company Limited	Metastin derivatives and use thereof
US20090093615A1 (en) *	2005-12-22	2009-04-09	Takeda Pharmaceutical Company Limited	Metastin derivatives and use thereof
MX2008012055A (es)	2006-03-20	2008-10-02	Merck & Co Inc	Agonistas del receptor de neuromedina u y usos de los mismos.
US20100215637A1 (en) *	2006-03-28	2010-08-26	Biopharmica Ltd	Agent for the Treatment of Hormone-Dependent Disorders and Uses Thereof
JO3048B1 (ar)	2006-10-25	2016-09-05	Takeda Pharmaceuticals Co	مشتقات متاستين واستخدامها
CA2701612A1 (fr) *	2007-10-05	2009-04-09	Takeda Pharmaceutical Company Limited	Derive de neuromedine u
EP2277900A4 (fr)	2008-04-24	2011-08-03	Takeda Pharmaceutical	Dérivé de métastine et son utilisation
EP2340047A1 (fr)	2008-09-19	2011-07-06	Nektar Therapeutics	Conjugués de polymère de peptides kiss1

2005
- 2005-06-23 CA CA002571420A patent/CA2571420A1/fr not_active Abandoned
- 2005-06-23 PE PE2005000728A patent/PE20060371A1/es not_active Application Discontinuation
- 2005-06-23 RU RU2006145886/04A patent/RU2006145886A/ru not_active Application Discontinuation
- 2005-06-23 NZ NZ552029A patent/NZ552029A/en not_active IP Right Cessation
- 2005-06-23 SG SG200904360-5A patent/SG153865A1/en unknown
- 2005-06-23 EP EP09075257.7A patent/EP2113513B1/fr not_active Expired - Lifetime
- 2005-06-23 AU AU2005257484A patent/AU2005257484A1/en not_active Abandoned
- 2005-06-23 BR BRPI0512397-6A patent/BRPI0512397A/pt not_active IP Right Cessation
- 2005-06-23 JP JP2006554374A patent/JP4346650B2/ja not_active Expired - Fee Related
- 2005-06-23 EP EP05755666A patent/EP1758932A2/fr not_active Withdrawn
- 2005-06-23 MX MXPA06014206A patent/MXPA06014206A/es unknown
- 2005-06-23 WO PCT/JP2005/012021 patent/WO2006001499A2/fr not_active Ceased
- 2005-06-23 PE PE2009000637A patent/PE20091567A1/es not_active Application Discontinuation
- 2005-06-23 US US11/630,698 patent/US7625869B2/en not_active Expired - Fee Related
- 2005-06-23 TW TW094120917A patent/TW200607816A/zh unknown
- 2005-06-23 CN CN200910225195A patent/CN101845091A/zh active Pending
- 2005-06-23 AR ARP050102591A patent/AR049938A1/es unknown
- 2005-06-23 CN CN200910225194A patent/CN101863971A/zh active Pending
2006
- 2006-11-27 IL IL179640A patent/IL179640A0/en unknown
- 2006-12-21 NO NO20065957A patent/NO20065957L/no not_active Application Discontinuation
- 2006-12-22 CR CR8828A patent/CR8828A/es not_active Application Discontinuation
- 2006-12-28 MA MA29567A patent/MA28903B1/fr unknown
2008
- 2008-09-25 JP JP2008245073A patent/JP4654284B2/ja not_active Expired - Fee Related
- 2008-10-01 US US12/286,671 patent/US8778871B2/en active Active
- 2008-12-15 CL CL2008003730A patent/CL2008003730A1/es unknown
2009
- 2009-06-01 JP JP2009132363A patent/JP2009227687A/ja active Pending

Also Published As

Publication number	Publication date
EP2113513A3 (fr)	2010-11-03
PE20091567A1 (es)	2009-11-03
IL179640A0 (en)	2007-05-15
EP2113513A2 (fr)	2009-11-04
SG153865A1 (en)	2009-07-29
JP4346650B2 (ja)	2009-10-21
WO2006001499A2 (fr)	2006-01-05
AR049938A1 (es)	2006-09-13
JP2008506632A (ja)	2008-03-06
US8778871B2 (en)	2014-07-15
BRPI0512397A (pt)	2008-03-04
WO2006001499A3 (fr)	2006-03-02
CA2571420A1 (fr)	2006-01-05
MXPA06014206A (es)	2007-02-14
CN101863971A (zh)	2010-10-20
RU2006145886A (ru)	2008-06-27
EP2113513B1 (fr)	2016-05-18
CN101845091A (zh)	2010-09-29
MA28903B1 (fr)	2007-10-01
US7625869B2 (en)	2009-12-01
EP1758932A2 (fr)	2007-03-07
US20080312155A1 (en)	2008-12-18
JP4654284B2 (ja)	2011-03-16
JP2009227687A (ja)	2009-10-08
CR8828A (es)	2007-07-19
TW200607816A (en)	2006-03-01
AU2005257484A1 (en)	2006-01-05
JP2009024028A (ja)	2009-02-05
PE20060371A1 (es)	2006-06-15
NZ552029A (en)	2009-01-31
US20090298765A1 (en)	2009-12-03
CL2008003730A1 (es)	2009-05-04

Legal Events

Date	Code	Title	Description
2012-01-23	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20065957L (no)	2007-01-25	Metastinderivater og anvendelse derav
DK3911648T3 (da)	2025-01-13	6'-[[(1s,3s)-3-[[5-(difluormethoxy)-2-pyrimidinyl]amino]cyclopentyl]amino][1(2h),3'-bipyridin]-2-on som pcsk9-hæmmer og fremgangsmåder til anvendelse deraf
DK1799235T3 (da)	2013-02-11	Sammensætninger af fosterhudcelleprotein til behandling af hudtilstande, -lidelser eller -sygdomme og fremgangsmåder til fremstilling og anvendelse deraf
EA200870446A1 (ru)	2009-04-28	Пиридон сульфонамиды и пиридон сульфамиды в качестве ингибиторов мек
DK1751302T3 (da)	2012-07-16	Analytsensorer og fremgangsmåder til fremstilling og anvendelse heraf
EA200801291A1 (ru)	2008-12-30	Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
DK2089369T3 (da)	2011-05-09	2,4-pyrimidindiaminderivater som hæmmere af JAK-kinaser til behandling af autoimmune sygdomme
NO20082595L (no)	2008-09-22	Metastinderivater og deres anvendelse derav
WO2009143024A3 (fr)	2010-01-07	Composés et procédés de modulation des kinases, et indications associées
TN2009000128A1 (en)	2010-10-18	Dihydropyridine derivatives useful as protein kinase inhibitors
NO20070983L (no)	2007-02-27	Stabil injiserbar blanding av alfa-tokoferylsuksinat, analoger og salter derav
MXPA06011327A (es)	2006-12-15	Azaindoles utiles como inhibidores de jak y otras proteinas cinasas.
NO20076413L (no)	2008-02-11	Multisykliske forbindelser og fremgangsmater for deres anvendelse
NO20064976L (no)	2006-10-31	Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
EA200802213A1 (ru)	2009-10-30	Способы лечения заболеваний крови
EP1584923A3 (fr)	2006-01-04	Stabilisation de biomolecules dans des échantillons
NO20062876L (no)	2006-08-08	Sammensetninger til kombinert radio- og kjemoterapi, og fremgangsmater
MY175797A (en)	2020-07-09	Agonists of src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the same
MY144970A (en)	2011-11-30	Heterocyclic compounds
NO20081713L (no)	2008-06-04	Pyrimidinderivater og deres anvendelse som KCNQ-kaliumkanalapnere
NO20070640L (no)	2007-04-11	Forbedrede aprotininvananter
MX2008001538A (es)	2008-04-04	Aril piridinas y metodos para su uso.
EA200800357A1 (ru)	2008-06-30	Новые фармацевтические соединения
UA87494C2 (en)	2009-07-27	Azaindoles useful as inhibitors of jak and other protein kinases
EA200700648A1 (ru)	2007-10-26	4-((феноксиалкил)тио)феноксиуксусные кислоты и аналоги